Nova Wealth Management Inc. Has $62,000 Stake in Thermo Fisher Scientific Inc. $TMO

Nova Wealth Management Inc. reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 19.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 154 shares of the medical research company’s stock after selling 38 shares during the period. Nova Wealth Management Inc.’s holdings in Thermo Fisher Scientific were worth $62,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. Douglas Lane & Associates LLC grew its position in Thermo Fisher Scientific by 6.6% in the 2nd quarter. Douglas Lane & Associates LLC now owns 199,531 shares of the medical research company’s stock valued at $80,902,000 after purchasing an additional 12,333 shares during the period. RDA Financial Network grew its position in Thermo Fisher Scientific by 1.6% in the 2nd quarter. RDA Financial Network now owns 4,399 shares of the medical research company’s stock valued at $1,784,000 after purchasing an additional 68 shares during the period. HBW Advisory Services LLC grew its position in Thermo Fisher Scientific by 2.0% in the 2nd quarter. HBW Advisory Services LLC now owns 2,376 shares of the medical research company’s stock valued at $963,000 after purchasing an additional 46 shares during the period. Doliver Advisors LP grew its position in Thermo Fisher Scientific by 28.7% in the 2nd quarter. Doliver Advisors LP now owns 3,742 shares of the medical research company’s stock valued at $1,517,000 after purchasing an additional 835 shares during the period. Finally, Jacobs & Co. CA grew its position in Thermo Fisher Scientific by 13.6% in the 2nd quarter. Jacobs & Co. CA now owns 17,507 shares of the medical research company’s stock valued at $7,098,000 after purchasing an additional 2,090 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 2.4%

NYSE TMO opened at $479.48 on Monday. The stock has a market capitalization of $181.06 billion, a price-to-earnings ratio of 27.73, a PEG ratio of 2.56 and a beta of 0.75. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The business’s fifty day moving average is $466.86 and its 200-day moving average is $450.58.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. During the same period in the previous year, the business posted $5.37 EPS. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.95%.

Analyst Ratings Changes

Several research firms recently issued reports on TMO. William Blair began coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating for the company. HSBC reaffirmed a “hold” rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Evercore ISI cut their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. UBS Group lifted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a report on Thursday, July 24th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $592.24.

Insider Activity

In other news, CEO Marc N. Casper sold 400 shares of the company’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last ninety days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.